STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp Stock Price, News & Analysis

INCY NYSE

Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.

Incyte Corporation (INCY) is a global biopharmaceutical leader focused on innovative therapies in oncology, dermatology, and immunology. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical developments, regulatory milestones, and strategic initiatives.

Access authoritative information about FDA approvals, clinical trial results, and research collaborations that shape Incyte's pipeline of small-molecule therapies. Our curated collection includes earnings announcements, partnership disclosures, and scientific advancements across therapeutic areas of focus.

Stay informed about developments in blood cancer treatments, autoimmune disorder therapies, and dermatological innovations through verified press releases and objective reporting. This resource serves as your primary source for tracking Incyte's progress in addressing unmet medical needs through targeted therapeutic solutions.

Bookmark this page for streamlined access to critical updates that impact investment decisions and industry understanding. Check regularly for new developments in Incyte's evolving portfolio of proprietary medicines and global healthcare partnerships.

News

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Rhea-AI Summary
QIAGEN (QGEN) and Incyte (INCY) have announced a global collaboration to develop a novel diagnostic panel for myeloproliferative neoplasms (MPNs). The partnership focuses on creating a multimodal panel using next-generation sequencing technology to detect gene alterations in blood cancers, particularly targeting mutant calreticulin (mutCALR). The panel will support Incyte's drug portfolio, including INCA033989, and will be validated on Illumina's NextSeq 550Dx platform. QIAGEN will handle regulatory submissions and market access across the US, EU, and Asia-Pacific regions. The collaboration aims to improve treatment decisions for MPN patients, which represent about 40% of hematological malignancies, by enabling precise identification of genomic aberrations in biomarkers like CALR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Rhea-AI Summary
Incyte announced groundbreaking clinical data for INCA033989, their first-in-class mutCALR-targeted monoclonal antibody therapy for essential thrombocythemia (ET). The late-breaking data presented at EHA2025 showed remarkable efficacy, with 86% of patients receiving doses ≥400mg achieving complete or partial hematologic response, and 82% reaching complete response. The drug demonstrated disease-modifying potential by selectively targeting and reducing mutCALR cells while promoting healthy blood cell production. In the study of 49 patients, 89% showed reduced mutCALR variant allele frequency. Safety profile was favorable with no dose-limiting toxicities, and 98% of patients maintained treatment. Most common side effects were mild, including fatigue (26.5%) and upper respiratory infections (20.4%). The company plans to initiate Phase 3 trials by early 2026 following regulatory discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Rhea-AI Summary
Incyte (INCY) announced the publication of Phase 3 POD1UM-303/InterAACT 2 trial results for Zynyz® (retifanlimab-dlwr) in The Lancet. The trial demonstrated significant benefits when combining retifanlimab with carboplatin-paclitaxel chemotherapy for treating advanced squamous cell carcinoma of the anal canal (SCAC). The study showed a 37% reduction in progression/death risk, with median progression-free survival of 9.3 months versus 7.4 months in the placebo group. Overall response rate improved to 55.8% with retifanlimab versus 44.2% with placebo. In May 2025, the FDA approved Zynyz® both in combination with chemotherapy for first-line treatment and as a single agent for advanced SCAC patients. Applications are under review by EMA and PMDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
clinical trial
News

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

Rhea-AI Summary
Specialised Therapeutics (ST) has expanded its partnership with Incyte to distribute two additional oncology therapies - axatilimab (Niktimvo) and retifanlimab (Zynyz) - in Australia, New Zealand, and Singapore. These medicines join the existing portfolio of Minjuvi and Pemazyre. Axatilimab, approved by FDA in August 2024, treats chronic graft-versus-host disease in patients who've had at least two prior treatments. Retifanlimab is approved for treating squamous cell carcinoma of the anal canal and Merkel cell carcinoma, with Australia having the highest MCC incidence globally. Under the agreement, Incyte will handle development and manufacturing, while ST will manage regulatory affairs, distribution, and local marketing. ST plans to submit both drugs for regulatory and reimbursement approval in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
partnership
-
News

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Incyte (INCY) has granted restricted stock unit awards (RSUs) totaling 16,550 shares to 19 new employees under its 2024 Inducement Stock Incentive Plan. The grants, effective June 2, 2025, were approved by the company's compensation committee as an inducement for new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent on continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
News

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Rhea-AI Summary
Incyte (INCY) announced multiple presentations at the 2025 European Hematology Association Congress in Milan, featuring late-breaking data for INCA033989, their novel mutCALR-directed monoclonal antibody for essential thrombocythemia (ET). The presentations include data from their hematology/oncology portfolio, with a key focus on INCA033989's potential as a disease-modifying treatment for myeloproliferative neoplasms. The congress will feature presentations on various programs including INCA035784, ruxolitinib, tafasitamab, axatilimab, INCB057643, and ponatinib. Incyte will host an analyst and investor event on June 15, 2025, from 6:00-7:30 a.m. EDT to discuss the mutCALR data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
News

Incyte to Present at Upcoming Investor Conference

Rhea-AI Summary

Incyte (Nasdaq: INCY) has announced its upcoming participation at the Goldman Sachs Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025 at 11:20 am ET. Investors and interested parties can access the live webcast through Investor.Incyte.com, with the replay remaining available for 30 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences
-
News

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Rhea-AI Summary
The FDA has approved Incyte's (NASDAQ: INCY) Zynyz® (retifanlimab-dlwr) as the first PD-1 inhibitor for advanced anal cancer treatment in the US. The approval covers two uses: first-line treatment in combination with chemotherapy for inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC), and as monotherapy for patients with disease progression on platinum-based chemotherapy. The Phase 3 trial showed a 37% reduction in progression/death risk, with median progression-free survival of 9.3 months vs 7.4 months for the placebo group. The treatment also demonstrated a 6.2-month improvement in median overall survival. In monotherapy, Zynyz achieved a 14% objective response rate and 49% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
fda approval
-
News

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Incyte (INCY) has granted equity incentives to 60 new employees under its 2024 Inducement Stock Incentive Plan. The awards, effective May 1, 2025, include: Restricted Stock Units (RSUs): - 33,413 shares of common stock - Vest 25% annually over 4 years Stock Options: - 8,951 shares at $62.03 per share exercise price - 10-year term - 25% vests after first year - Remaining 75% vests monthly over 36 months The compensation committee approved these grants as employment inducements under Nasdaq Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
News

Incyte to Present at Upcoming Investor Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences

FAQ

What is the current stock price of Incyte (INCY)?

The current stock price of Incyte (INCY) is $98.77 as of December 31, 2025.

What is the market cap of Incyte (INCY)?

The market cap of Incyte (INCY) is approximately 19.4B.
Stock INCY logo
Incyte Corp

NYSE:INCY

INCY Rankings

#619 Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

19.42B
192.26M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON